DGAP-News: Vivoryon Therapeutics AG
/ Key word(s): Quarter Results
14.05.2020 / 07:00
The issuer is solely responsible for the content of this announcement.
Vivoryon Therapeutics AG Reports First Quarter 2020
HALLE (SAALE) / MUNICH, Germany, 14 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today its first quarter business update for the period ending March 31, 2020. The first quarter 2020 report is available for download on the Company website: https://www.vivoryon.com/investors-news/financial-information.
– Vivoryon Therapeutics and Nordic Bioscience Entered into a Research and Development Collaboration
– Vivoryon Therapeutics Announced Update on Phase 2b Alzheimer’s Clinical Trial, VIVIAD
POST PERIOD HIGHLIGHTS
– Vivoryon Therapeutics Initiated Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer’s Disease
– Vivoryon Therapeutics Announced Outcome of Exclusive Option Deal with MorphoSys
Financial Review (According to IFRS)
All results are within management expectations.
Vivoryon Therapeutics held EUR 20.2 million in cash and cash equivalents and EUR 19.7 million in other short-term securities as of March 31, 2020.
Vivoryon Therapeutics and Nordic Bioscience entered into a Research and Development Collaboration
Vivoryon Therapeutics Announced an Update on Phase 2b Alzheimer’s Clinical Trial, VIVIAD
The primary endpoints of the study will assess the safety and tolerability of PQ912 in addition to its efficacy on working memory and attention. The secondary endpoints include long-term safety and tolerability of PQ912 and its efficacy on brain activity, cognition and daily activities.
Vivoryon has also added exploratory parameters selected with the rationale of advancing less invasive diagnostic technologies. This will include the Winterlight Labs speech assessment, the use of EEG to test neuronal network activity and connectivity, as well as a set of blood-based biomarkers run by Nordic Bioscience. The inclusion of these parameters will further strengthen PQ912’s data package and introduce more innovative and less demanding diagnostic tools to patients in the future.
POST PERIOD HIGHLIGHTS
Vivoryon Therapeutics Initiated Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer’s Disease
The collaboration will combine Vivoryon’s expertise in translating basic research into marketable small molecule therapeutics with the department’s focus on discovery and development of new treatment options that target recognized pathologic post-translational modifications.
Vivoryon Therapeutics Announced Outcome of Exclusive Option Deal with MorphoSys
Vivoryon Therapeutics’ Ordinary General Meeting of Shareholders postponed until September
For more information, please contact:
About Vivoryon Therapeutics AG
Forward Looking Statements
14.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Vivoryon Therapeutics AG|
|Phone:||+49 (0)345 555 9900|
|Fax:||+49 (0)345 555 9901|
|Listed:||Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam|
|EQS News ID:||1043541|
|End of News||DGAP News Service|